Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty - PubMed
4 hours ago
- #stem cell therapy
- #aging frailty
- #clinical trial
- Randomized phase 2b trial tested laromestrocel (MSCs) for aging frailty.
- Primary endpoint: 6-min walk test (6MWT) showed dose- and time-dependent improvements.
- Significant increase in 6MWT distance at month 9 (63.4 m, p = 0.0077).
- Correlation found between 6MWT and PROMIS Physical Function score.
- Decreased soluble TIE2 identified as a potential biomarker of responsiveness.
- Study suggests stem cell therapy may benefit patients with aging frailty.